ArticleCancer cell2016

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.

Xiumei Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.